How Skyrizi and Tremfya Work for Psoriasis
Skyrizi (risankizumab) targets interleukin-23 (IL-23), a cytokine driving inflammation in psoriasis. Tremfya (guselkumab) also blocks IL-23 but binds a different epitope, potentially affecting efficacy in some patients.[1][2] Both are biologics injected subcutaneously, approved for moderate-to-severe plaque psoriasis in adults.
Efficacy Head-to-Head: Which Clears Skin Better?
In the phase 3 ECLIPSE trial, Skyrizi showed superior skin clearance at week 16: 76% achieved PASI 90 (90% improvement in Psoriasis Area and Severity Index) versus 48% on Tremfya. PASI 100 rates were 47% for Skyrizi and 29% for Tremfya.[3] Long-term data up to week 52 maintained these differences, with Skyrizi at 86% PASI 90.[4] Real-world studies echo this, though head-to-head data remains limited beyond ECLIPSE.
Dosing Schedules: How Often Do Patients Inject?
Skyrizi requires two 150 mg starter doses at weeks 0 and 4, then every 12 weeks. Tremfya starts with 100 mg at weeks 0 and 4, then every 8 weeks.[1][2] Skyrizi's less frequent dosing suits patients preferring fewer injections.
| Aspect | Skyrizi | Tremfya |
|--------|---------|---------|
| Loading Doses | Weeks 0, 4 (150 mg each) | Weeks 0, 4 (100 mg each) |
| Maintenance | Every 12 weeks | Every 8 weeks |
| Annual Injections | ~9 | ~12 |
Safety and Side Effects: Common Risks for Patients
Both carry black-box warnings for infections and have similar adverse event profiles: upper respiratory infections (10-20%), headache (5-10%), and injection-site reactions (5-15%). Skyrizi reports slightly lower serious infection rates (1.5% vs. 2.1% for Tremfya in trials).[3][5] No major differences in malignancy or IBD risks, but monitor for hypersensitivity. Skyrizi may edge out in tolerability due to dosing.
Cost and Access: Insurance Coverage and Prices
List prices exceed $6,000 per dose for both, with annual costs around $70,000 before rebates.[6] Patient assistance programs exist from AbbVie (Skyrizi) and Janssen (Tremfya). Coverage is broad via Medicare Part D, but prior authorizations often require trial of cheaper options like Stelara. Skyrizi's patent expires in 2032; Tremfya's in 2033—check DrugPatentWatch.com for updates.[7]
When to Choose One Over the Other
Dermatologists often pick Skyrizi for faster, deeper clearance based on ECLIPSE, especially in patients valuing convenience.[8] Tremfya fits if quicker initial response matters or if Skyrizi fails (cross-efficacy seen in ~50% of switchers).[9] Neither is first-line; guidelines favor IL-17 inhibitors like Cosentyx for some profiles.
Sources
[1]: Skyrizi Prescribing Information - https://www.skyrizi.com/
[2]: Tremfya Prescribing Information - https://www.tremfya.com/
[3]: Gordon KB et al., Lancet (2018) - https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31773-8/fulltext
[4]: Reich K et al., J Am Acad Dermatol (2020)
[5]: FDA Labels Comparison
[6]: GoodRx Pricing Data (2023)
[7]: DrugPatentWatch.com - https://www.drugpatentwatch.com/
[8]: AAD Guidelines (2021)
[9]: Strober B et al., J Drugs Dermatol (2022)